SG10202110335PA - Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Info

Publication number
SG10202110335PA
SG10202110335PA SG10202110335PA SG10202110335PA SG 10202110335P A SG10202110335P A SG 10202110335PA SG 10202110335P A SG10202110335P A SG 10202110335PA SG 10202110335P A SG10202110335P A SG 10202110335PA
Authority
SG
Singapore
Prior art keywords
peptides
cancers
combination
immunotherapy against
against aml
Prior art date
Application number
Inventor
Andrea Mahr
Toni Weinschenk
Anita Wiebe
Oliver Schoor
Jens Fritsche
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG10202110335PA publication Critical patent/SG10202110335PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
SG10202110335P 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers SG10202110335PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319141P 2016-04-06 2016-04-06
GB201605872 2016-04-06

Publications (1)

Publication Number Publication Date
SG10202110335PA true SG10202110335PA (en) 2021-10-28

Family

ID=58503590

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202110335P SG10202110335PA (en) 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG10202008013TA SG10202008013TA (en) 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG11201808627RA SG11201808627RA (en) 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202008013TA SG10202008013TA (en) 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG11201808627RA SG11201808627RA (en) 2016-04-06 2017-04-05 Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Country Status (19)

Country Link
US (9) US10596240B2 (en)
EP (2) EP4219524A3 (en)
JP (3) JP6989136B2 (en)
KR (2) KR102411975B1 (en)
CN (1) CN109071605A (en)
AU (2) AU2017247607B2 (en)
BR (1) BR112018070067A2 (en)
CA (1) CA3020162A1 (en)
CL (4) CL2018002827A1 (en)
CO (1) CO2018011889A2 (en)
CR (1) CR20180530A (en)
IL (1) IL262081A (en)
MA (1) MA44605A (en)
MX (1) MX2018012152A (en)
MY (1) MY197258A (en)
PE (1) PE20181896A1 (en)
PH (1) PH12018502108A1 (en)
SG (3) SG10202110335PA (en)
TW (3) TWI727407B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115290806A (en) * 2022-08-01 2022-11-04 宁波工程学院 Method for solid-phase extraction of biogenic amine through hydrophilicity and cation exchange

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FI86437C (en) 1978-12-22 1992-08-25 Biogen Inc A FRUIT PROCEDURE FOR THE PREPARATION OF A POLYPEPTIDIDE WITH ANTIGENA EGENSKAPERNA HOS ETT HEPATITIS B- VIRUSANTIGEN.
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2138662T3 (en) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc PRODUCTION OF ANTIBODY FRAGMENTS.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU3001899A (en) * 1998-03-13 1999-09-27 Genos Biosciences, Inc. (zap-1) tumor associated genes and their uses
CA2393738A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
JP2004503213A (en) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド Single-stranded class I major histocompatibility complex, construct encoding the same and method of producing the same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CN101712721A (en) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T cell receptor fusions and conjugates and methods of use thereof
WO2002066501A2 (en) * 2001-01-02 2002-08-29 Hybrigenics PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005514029A (en) * 2001-11-07 2005-05-19 マンカインド コーポレイション Epitope synchronization in antigen-presenting cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2004097051A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
ATE461215T1 (en) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES THAT BIND TO DIFFERENT CLASS II HUMAN LEUCOCYTE ANTIGENS
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2458014A1 (en) 2010-09-07 2012-05-30 Rijksuniversiteit Groningen Prognostic markers for acute myeloid leukemia (AML)
BR112013010213A2 (en) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd antibodies that bind soluble t-cell receptor ligands
WO2013009818A2 (en) * 2011-07-11 2013-01-17 Gevo, Inc. High-performance ketol-acid reductoisomerases
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US10208086B2 (en) * 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP2015533473A (en) * 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド Individual cancer vaccine and adaptive immune cell therapy
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
ES2832546T3 (en) * 2013-01-15 2021-06-10 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 Peptides and Methods of Using Them
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI777195B (en) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
ES2749073T3 (en) * 2014-04-01 2020-03-19 Inst Nat Sante Rech Med An isolated donor peptide derived from MHC and its use
EP3495377A1 (en) * 2014-04-01 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
MA43482A1 (en) * 2016-04-06 2019-05-31 Immatics Biotechnologies Gmbh Novel Peptides and Peptide Combination for Use in Immunotherapy for Acute Myeloid Leukemia (IMA) and Other Cancers

Also Published As

Publication number Publication date
US10596241B2 (en) 2020-03-24
EP3440095A1 (en) 2019-02-13
CL2018002827A1 (en) 2018-11-16
US20190275129A1 (en) 2019-09-12
US20200138924A1 (en) 2020-05-07
CN109071605A (en) 2018-12-21
US20200316182A1 (en) 2020-10-08
IL262081A (en) 2018-11-29
JP6989136B2 (en) 2022-01-05
US20220313807A1 (en) 2022-10-06
SG11201808627RA (en) 2018-10-30
US20220105165A1 (en) 2022-04-07
BR112018070067A2 (en) 2019-02-12
JP2021045150A (en) 2021-03-25
AU2017247607A1 (en) 2018-10-11
CL2020002171A1 (en) 2020-12-11
AU2017247607B2 (en) 2021-08-19
CR20180530A (en) 2019-03-11
SG10202008013TA (en) 2020-10-29
CL2020002174A1 (en) 2021-01-08
US10835588B2 (en) 2020-11-17
TW202116792A (en) 2021-05-01
JP2023030082A (en) 2023-03-07
US10722565B2 (en) 2020-07-28
CA3020162A1 (en) 2017-10-12
TWI782375B (en) 2022-11-01
PE20181896A1 (en) 2018-12-11
US10835587B2 (en) 2020-11-17
MY197258A (en) 2023-06-08
JP2019519197A (en) 2019-07-11
US20210085767A1 (en) 2021-03-25
AU2021212132A1 (en) 2021-08-26
KR20220097524A (en) 2022-07-07
TW202014434A (en) 2020-04-16
AU2021212132B2 (en) 2023-05-11
TWI727407B (en) 2021-05-11
TW202246303A (en) 2022-12-01
KR102411975B1 (en) 2022-06-22
MX2018012152A (en) 2019-02-07
US20200323967A1 (en) 2020-10-15
MA44605A (en) 2019-02-13
US10799570B2 (en) 2020-10-13
EP4219524A3 (en) 2023-10-18
US20200046819A1 (en) 2020-02-13
PH12018502108A1 (en) 2019-09-09
CO2018011889A2 (en) 2018-11-13
US20190262445A1 (en) 2019-08-29
KR20180132817A (en) 2018-12-12
EP4219524A2 (en) 2023-08-02
US10596240B2 (en) 2020-03-24
CL2020002173A1 (en) 2020-12-11

Similar Documents

Publication Publication Date Title
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1259376A1 (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
IL257331A (en) Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202007962RA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
SG11201706681VA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG11201706155XA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
HK1255542A1 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
IL261786A (en) Peptides and combination of peptides for use in immunotherapy against cancers
HK1246181A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL269813A (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
IL280879A (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
HK1255541A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL262081A (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers